Doctor showing tablet to patient. Management of metastatic renal cell carcinoma should be highly individualized, according to investigators. Preoperative systemic therapy does not lead to worse ...

AUSTIN, Texas -- Cytoreductive nephrectomy improved overall survival (OS) by more than a year for patients with metastatic renal cell carcinoma (mRCC) with sarcomatoid or rhabdoid (S/R) ...

Credit: Getty Images With effective modern systemic therapies for metastatic RCC, how cytoreductive nephrectomy affects quality of life has become an increasingly relevant question, according to ...

Researchers writing in JAMA Network Open report that for patients with metastatic clear cell renal cell carcinoma, removing the kidney and its primary tumor is not associated with improved overall ...

A Canadian study recently assessed 709 patients with intermediate- and high-risk synchronous mRCC with or without sarcomatoid features. Most patients had clear cell histology and were treated with ...

Clinicopathological features and prognosis of MED15-TFE3 rearrangement renal cell carcinoma: An updated report. Updated outcomes of patients with metastatic non-clear cell renal cell carcinoma ...

Please provide your email address to receive an email when new articles are posted on . In this video, Mark W. Ball, MD, discusses the ongoing SWOG S1931 study assessing the use of immune checkpoint ...

Although retrospective data supported a similar survival benefit for cytoreductive nephrectomy in the targeted therapy era as it did for the initial immunotherapy era (1992 to 2006), level 1 evidence ...

Dr. Hyung L. Kim discusses how the addition of cytoreductive nephrectomy to ICI therapy may affect survival and quality of life those with kidney cancer. A cytoreductive nephrectomy is a surgery which ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. There's a multicentered trial called ...

Clinically significant developments in RCC presented at ASCO GU, including insights into the growing importance of HIF-2α inhibition, are discussed by Dr Brian Rini of Vanderbilt University.

Surgery to remove a cancerous kidney can often lengthen the lives of patients receiving targeted therapy for metastatic kidney cancer, but only about three in ten such patients undergo the procedure, ...